File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: Is it appropriate?

TitleUse of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: Is it appropriate?
Authors
KeywordsAngelica sinensis
Breast cancer
Dong quai
Estrogen receptor
Herbal therapy
Menopause
Issue Date2005
Citation
Menopause, 2005, v. 12, n. 6, p. 734-740 How to Cite?
AbstractObjective: Regarding the growing use of alternative therapies for peri- or postmenopausal symptoms, we evaluated the effect of a water extract of Angelica sinensis (dong quai), used for peri-or postmenopausal relief, on the proliferation of estrogen receptor-positive (MCF-7) and negative (BT-20) breast cancer cells in vitro. Design: The present study was designed to investigate the growth-modulating effect of dong quai water extract, alone or in the presence of 17β-estradiol and 4-hydroxytamoxifen, on MCF-7 and BT-20 cell cultures using MTT proliferation assay. Results: The water extract of dong quai dose-dependently and significantly stimulated the proliferation of MCF-7 cells with a weak estrogen-agonistic activity in the presence of 17β-estradiol, as evidenced by the significant suppression by 4-hydroxytamoxifen. Meanwhile, the extract significantly exerted a growth-stimulating effect on BT-20 in a dose-dependent manner with or without 17β-estradiol. No obvious difference was found in the growth of BT-20 cells treated with the extract in the presence of 17β-estradiol or 4-hydroxytamoxifen. Conclusions: The water extract of dong quai stimulated the growth of MCF-7 cells, possibly dependent of weak estrogen-agonistic activity, and augmented the BT-20 cell proliferation independent of estrogen receptor-mediated pathway. The present study provides data regarding the estrogen-like activity of dong quai, which might assist in decision making on herbal therapy use by women at risk for both estrogen-sensitive and insensitive breast cancer. Because of the lack of clinical data demonstrating the potential side effects of dong quai, its use in herbal preparations for the treatment of peri- or postmenopausal symptoms, especially in women with breast cancer, warrants caution pending further study. © 2005 The North American Menopause Society.
Persistent Identifierhttp://hdl.handle.net/10722/343011
ISSN
2023 Impact Factor: 2.8
2023 SCImago Journal Rankings: 0.984

 

DC FieldValueLanguage
dc.contributor.authorLau, Clara B.S.-
dc.contributor.authorHo, Tony C.Y.-
dc.contributor.authorChan, Terry W.L.-
dc.contributor.authorKim, Stephen C.F.-
dc.date.accessioned2024-05-10T09:04:45Z-
dc.date.available2024-05-10T09:04:45Z-
dc.date.issued2005-
dc.identifier.citationMenopause, 2005, v. 12, n. 6, p. 734-740-
dc.identifier.issn1072-3714-
dc.identifier.urihttp://hdl.handle.net/10722/343011-
dc.description.abstractObjective: Regarding the growing use of alternative therapies for peri- or postmenopausal symptoms, we evaluated the effect of a water extract of Angelica sinensis (dong quai), used for peri-or postmenopausal relief, on the proliferation of estrogen receptor-positive (MCF-7) and negative (BT-20) breast cancer cells in vitro. Design: The present study was designed to investigate the growth-modulating effect of dong quai water extract, alone or in the presence of 17β-estradiol and 4-hydroxytamoxifen, on MCF-7 and BT-20 cell cultures using MTT proliferation assay. Results: The water extract of dong quai dose-dependently and significantly stimulated the proliferation of MCF-7 cells with a weak estrogen-agonistic activity in the presence of 17β-estradiol, as evidenced by the significant suppression by 4-hydroxytamoxifen. Meanwhile, the extract significantly exerted a growth-stimulating effect on BT-20 in a dose-dependent manner with or without 17β-estradiol. No obvious difference was found in the growth of BT-20 cells treated with the extract in the presence of 17β-estradiol or 4-hydroxytamoxifen. Conclusions: The water extract of dong quai stimulated the growth of MCF-7 cells, possibly dependent of weak estrogen-agonistic activity, and augmented the BT-20 cell proliferation independent of estrogen receptor-mediated pathway. The present study provides data regarding the estrogen-like activity of dong quai, which might assist in decision making on herbal therapy use by women at risk for both estrogen-sensitive and insensitive breast cancer. Because of the lack of clinical data demonstrating the potential side effects of dong quai, its use in herbal preparations for the treatment of peri- or postmenopausal symptoms, especially in women with breast cancer, warrants caution pending further study. © 2005 The North American Menopause Society.-
dc.languageeng-
dc.relation.ispartofMenopause-
dc.subjectAngelica sinensis-
dc.subjectBreast cancer-
dc.subjectDong quai-
dc.subjectEstrogen receptor-
dc.subjectHerbal therapy-
dc.subjectMenopause-
dc.titleUse of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: Is it appropriate?-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.gme.0000184419.65943.01-
dc.identifier.pmid16278617-
dc.identifier.scopuseid_2-s2.0-27944466104-
dc.identifier.volume12-
dc.identifier.issue6-
dc.identifier.spage734-
dc.identifier.epage740-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats